Login / Signup

Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus?

Petr PrasilRadek SlehaMarian KacerovskyPavel Bostik
Published in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2023)
 = 1.00, respectively). However, although the isolated neurotoxicity of spiramycin was the only significant adverse reaction demonstrated in this study, pyrimethamine/sulfadiazine therapy should be preferred, because it is known to be more effective and with limited adverse reactions.
Keyphrases
  • adverse drug
  • plasmodium falciparum
  • emergency department
  • bone marrow
  • stem cells
  • mesenchymal stem cells
  • decision making
  • replacement therapy
  • cell therapy
  • pregnancy outcomes
  • electronic health record